1 Ocak 2020 Dergi makalesi Açık Erişim

Zencir, Sevil; Hsieh, Meng-Hsun; Hsu, Joel-Sean; Ergun, Yavuz; Chou, Guan-Ling; Li, Tsai-Kun; Teng, Shu-Chun; Topcu, Zeki

MARC21 XML

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Hsieh, Meng-Hsun</subfield>
    <subfield code="u">Natl Taiwan Univ, Coll Med, Dept Microbiol, Taipei 10051, Taiwan</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Hsu, Joel-Sean</subfield>
    <subfield code="u">Natl Taiwan Univ, Coll Med, Dept Microbiol, Taipei 10051, Taiwan</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Ergun, Yavuz</subfield>
    <subfield code="u">Dokuz Eylul Univ, Fac Sci, Dept Chem, TR-35160 Izmir, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Chou, Guan-Ling</subfield>
    <subfield code="u">Natl Taiwan Univ, Coll Med, Dept Microbiol, Taipei 10051, Taiwan</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Li, Tsai-Kun</subfield>
    <subfield code="u">Natl Taiwan Univ, Coll Med, Dept Microbiol, Taipei 10051, Taiwan</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Teng, Shu-Chun</subfield>
    <subfield code="u">Natl Taiwan Univ, Coll Med, Dept Microbiol, Taipei 10051, Taiwan</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Topcu, Zeki</subfield>
    <subfield code="u">Ege Univ, Fac Pharm, Dept Pharmaceut Biotechnol, TR-35100 Izmir, Turkey</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="4">
    <subfield code="p">JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY</subfield>
    <subfield code="v">146</subfield>
    <subfield code="n">7</subfield>
    <subfield code="c">1671-1676</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution</subfield>
    <subfield code="u">http://www.opendefinition.org/licenses/cc-by</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.1007/s00432-020-03213-x</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase-negative cells</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Zencir, Sevil</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="o">oai:zenodo.org:5665</subfield>
    <subfield code="p">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="2">opendefinition.org</subfield>
    <subfield code="a">cc-by</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2020-01-01</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="u">https://aperta.ulakbim.gov.trrecord/5665/files/bib-f154af53-fa5b-4ed4-84b4-3cee694af7c8.txt</subfield>
    <subfield code="z">md5:5f31ecf13f8340026603f87745eda06b</subfield>
    <subfield code="s">319</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <controlfield tag="005">20210315061458.0</controlfield>
  <controlfield tag="001">5665</controlfield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">Background DNA topoisomerase and telomerase enzymes are popular targets of several anti-tumor drugs. Smooth proceeding of telomeric recombination requires Topoisomerase II (Top2), which is involved in telomere-telomere recombination through functioning in relaxation of positive supercoils among the cells adopting telomerase-independent Alternative lengthening of telomere (ALT) pathway. Most of the inhibitors reported so far have been designed to targetsolely telomerase-positive cells, which can potentially lead to therapeutic failure because tumor cells treated with telomerase inhibitors can activate the ALT pathway for telomere maintenance. Knowing that ALT cells are more sensitive against a Top2 inhibitor, ICRF-93 agent, compared to telomerase-positive cells, we analyzed two selected ellipticine derivatives that we recently reported as TopII-targeting compounds, to assess their effects on the formation of DNA breaks and suppression of ALT pathway. Methods Cell viability, Comet, C-Circle assays, dot blot, immunofluorescence staining, and telomere fluorescence in situ hybridization (FISH) staining were used for determining the effect of the compounds on ALT status of tumor cells. Results and conclusions Treatment of ALT cells with ellipticine derivatives resulted in the formation of DNA breaks and suppression of ALT-associated phenotypes in vitro. Our results will contribute to the development of therapeutic strategies combining telomerase and ALT pathway inhibitors.</subfield>
  </datafield>
</record>